1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Trump Signs Bill Bolstering US FDA Device Center Funding By 2% To $8M

 
• By Sue Darcey

The FDA’s device center is getting a 2% boost after President Trump on 20 December signed off on all appropriations bills for fiscal year 2020.

United States Capitol on 50 Dollars bill USA money banknote

The US Food and Drug Administration's Center for Devices and Radiological Health (CDRH) will receive an additional $8m, or a 2% boost, in FY2020 funding after President Trump signed a new spending package into law on 20 December. All FDA spending will rise from a total of $3.07bn in FY2019 to $3.16bn in FY2020, an increase of approximately 3%. A key provision of the bill repealed the medical device excise tax that the medical device industry has been fighting against for the past seven years. (Also see "After Seven Years Device Tax Repeal Looks Certain" - Medtech Insight, 17 December, 2019.)

Besides congressional funding, the FDA's device center is expected to raise $219m in medical device user fees, which will bring...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

House Bill Calls For ‘Non-Flushable’ Label On Personal Wipes

 
• By Eileen Francis

The US House of Representatives passes legislation requiring manufacturers of non-flushable wet wipes to label products as ‘non-flushable," a move endorsed by the Personal Care Products Council.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 
• By Brian Bossetta

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

More from Policy & Regulation

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By Ashley Yeo

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.

FDA ‘Regulatory Accelerator’ Aims To Speed Digital Health Development

 
• By Elizabeth Orr

The US FDA has launched the Regulatory Accelerator to expedite digital health product development. This includes resources like a Resource Index for Innovators, a Medical Device Software Guidance Navigator, and best practices for early meetings.

From ‘Work Harder’ to ‘Phenomenal People’: Makary’s FDA About-Face

 
• By Michael McCaughan

In his first 100 days as FDA commissioner, Martin Makary has gone from vocal critic to vocal supporter of the agency’s staff, calling them “phenomenal” and praising their dedication—even as morale remains shaken by recent layoffs and restructuring.